Last reviewed · How we verify
NCT03628651
Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
trial testing Blood Sample Collection in Hepatocellular Carcinoma in 2,150 participants. Completed in 11 March 2020.
11 March 2020
Quick facts
| Lead sponsor | Exact Sciences Corporation |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,150 |
| Start date | 2 April 2018 |
| Primary completion | 11 March 2020 |
| Estimated completion | 11 March 2020 |
| Sites | 74 locations across France, Italy, Taiwan, Germany, Thailand, United States, Spain |
Drugs / interventions tested
- Blood Sample Collection — full drug profile →
- Blood Sample Collection — full drug profile →
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
- Hepatocellular Carcinoma Surveillance — all drugs for Hepatocellular Carcinoma Surveillance →
Sponsor
Exact Sciences Corporation
Who can join
18 and older, any sex, with Hepatocellular Carcinoma or Hepatocellular Carcinoma Surveillance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to obtain de-identified, clinically-characterized whole blood specimens for use in developing and evaluating the performance of new biomarker assays for detection of hepatocellular carcinoma (HCC).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma.
Chalasani NP, Porter K, Bhattacharya A, Book AJ, et al · · 2022 · cited 116× · PMID 34391922 · DOI 10.1016/j.cgh.2021.08.010 -
A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma.
Chalasani NP, Ramasubramanian TS, Bhattacharya A, Olson MC, et al · · 2021 · cited 100× · PMID 32889146 · DOI 10.1016/j.cgh.2020.08.065 -
Using cell-free DNA for HCC surveillance and prognosis.
Tran NH, Kisiel J, Roberts LR. · · 2021 · cited 37× · PMID 34136776 · DOI 10.1016/j.jhepr.2021.100304 -
Circulating Tumor DNA and Hepatocellular Carcinoma.
Yang JD, Liu MC, Kisiel JB. · · 2019 · cited 29× · PMID 31226727 · DOI 10.1055/s-0039-1688503 -
The Current Status of the Liver Liquid Biopsy in MASH Related HCC: Overview and Future Directions.
Ugonabo O, Udoh US, Rajan PK, Reeves H, et al · · 2023 · cited 10× · PMID 37759769 · DOI 10.3390/biom13091369 -
Circulating Metabolic Markers Related to the Diagnosis of Hepatocellular Carcinoma.
Xie D, Zhang G, Ma Y, Wu D, et al · · 2022 · cited 8× · PMID 36532884 · DOI 10.1155/2022/7840606 -
Blood biomarkers of hepatocellular carcinoma: a critical review.
Zhao J, Hu Z, Zheng X, Lin Y, et al · · 2024 · cited 4× · PMID 39650722 · DOI 10.3389/fcell.2024.1489836 -
New insights into biomarkers and risk stratification to predict hepatocellular cancer.
Li K, Mathew B, Saldanha E, Ghosh P, et al · · 2025 · cited 3× · PMID 40269686 · DOI 10.1186/s10020-025-01194-6
Verify or expand the search:
- PubMed search for NCT03628651
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood Sample Collection
Trials testing the same drug.
- NCT07436637 — Guardant Shield Colorectal Cancer Screening · NA · not yet recruiting
- NCT07054346 — Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 · Phase 1 · recruiting
- NCT06695494 — Enabling Genomic Testing in Cancer of Unknown Primary · recruiting
- NCT07405515 — Pathophysiology of Dysautonomia and Postural Tachycardia Syndrome (POTS) in Post-viral Syndromes and COVID-19 · NA · active not recruiting
- NCT05487248 — A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients · NA · active not recruiting
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other Exact Sciences Corporation trials
Trials by the same sponsor.
- NCT05246839 — Informed Choice - Compass · terminated
- NCT05210283 — CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer · active not recruiting
- NCT04473625 — Stool Collection Sub-Study of Exact Sciences Protocol 2018-01 · completed
- NCT04395391 — Home Usability Study of the SARS-CoV-2 (COVID-19) Test · completed
- NCT04213326 — Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03628651 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Exact Sciences Corporation
- Last refreshed: 6 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03628651.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing